David C Dale1. 1. Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195, USA. dcdale@u.washington.edu
Abstract
PURPOSE OF REVIEW: The present review updates treatment of neutropenia from articles published from January 2008 through April 2009. RECENT FINDINGS: Chemotherapy-induced neutropenia occurs most commonly in the first cycle of treatment. Older patients, patients with multiple comorbidities, and those receiving more myelotoxic drugs are prone to develop neutropenia and its complications. Current guidelines recommend the prophylactic use of the myeloid growth factors for the first cycle of chemotherapy for patients with more than a 20% risk of febrile neutropenia. Meta analysis from randomized trials shows that granulocyte colony-stimulating factor prophylaxis is associated with patients receiving more intensive chemotherapy, having better survival, but also having a higher risk of secondary acute myeloid leukemia. Antibiotics are standard treatment of febrile neutropenia and are increasingly used for prophylaxis in 'low-risk' patients. SUMMARY: The myeloid growth factor granulocyte colony-stimulating factor has radically changed our approach to the prevention of febrile neutropenia. Antibiotics remain the mainstay of treatment of febrile neutropenia.
PURPOSE OF REVIEW: The present review updates treatment of neutropenia from articles published from January 2008 through April 2009. RECENT FINDINGS: Chemotherapy-induced neutropenia occurs most commonly in the first cycle of treatment. Older patients, patients with multiple comorbidities, and those receiving more myelotoxic drugs are prone to develop neutropenia and its complications. Current guidelines recommend the prophylactic use of the myeloid growth factors for the first cycle of chemotherapy for patients with more than a 20% risk of febrile neutropenia. Meta analysis from randomized trials shows that granulocyte colony-stimulating factor prophylaxis is associated with patients receiving more intensive chemotherapy, having better survival, but also having a higher risk of secondary acute myeloid leukemia. Antibiotics are standard treatment of febrile neutropenia and are increasingly used for prophylaxis in 'low-risk' patients. SUMMARY: The myeloid growth factor granulocyte colony-stimulating factor has radically changed our approach to the prevention of febrile neutropenia. Antibiotics remain the mainstay of treatment of febrile neutropenia.
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Scott D Ramsey; Zhimei Liu; Rob Boer; Sean D Sullivan; Jennifer Malin; Quan V Doan; Robert W Dubois; Gary H Lyman Journal: Value Health Date: 2008-07-31 Impact factor: 5.725
Authors: Philip S Rosenberg; Blanche P Alter; Daniel C Link; Steven Stein; Elin Rodger; Audrey A Bolyard; Andrew A Aprikyan; Mary A Bonilla; Yigal Dror; George Kannourakis; Peter E Newburger; Laurence A Boxer; David C Dale Journal: Br J Haematol Date: 2007-11-20 Impact factor: 6.998
Authors: Michael Wang; Meletios A Dimopoulos; Christine Chen; M Teresa Cibeira; Michel Attal; Andrew Spencer; S Vincent Rajkumar; Zhinuan Yu; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight; Donna M Weber Journal: Blood Date: 2008-09-17 Impact factor: 22.113
Authors: Jeffrey Crawford; David C Dale; Nicole M Kuderer; Eva Culakova; Marek S Poniewierski; Debra Wolff; Gary H Lyman Journal: J Natl Compr Canc Netw Date: 2008-02 Impact factor: 11.908
Authors: Silvia Wicki; André Keisker; Christoph Aebi; Kurt Leibundgut; Andreas Hirt; Roland A Ammann Journal: Pediatr Blood Cancer Date: 2008-12 Impact factor: 3.167
Authors: Alena M Pfeil; Kim Allcott; Ruth Pettengell; Gunter von Minckwitz; Matthias Schwenkglenks; Zsolt Szabo Journal: Support Care Cancer Date: 2014-10-07 Impact factor: 3.603